1110.HK
Kingworld Medicines Group Limited [1110.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
1110.HK Stock Summary
In the News
1110.HK Financial details
Company Rating
Strong Buy
Market Cap
296.23M
Income
36.26M
Revenue
1.09B
Book val./share
1.13
Cash/share
0.46
Dividend
0.02
Dividend %
4.28%
Employees
1K
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
8.25
Forward P/E
-
PEG
-3.03
P/S
0.36
P/B
0.58
P/C
1.11
P/FCF
3.65
Quick Ratio
0.47
Current Ratio
1.15
Debt / Equity
0.45
LT Debt / Equity
0.01
-
-
EPS (TTM)
0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-14.93%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.73%
Revenue last 5Y
-2.35%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
3%
ROE
7%
ROC
0.1%
Gross Margin
29%
Oper. Margin
8%
Profit Margin
5%
Payout
31%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.485-0.92
52W High
-
52W Low
-
RSI
45
Rel Volume
7.19
Avg Volume
142.92K
Volume
1.03M
Perf Week
-1.92%
Perf Month
-5.56%
Perf Quarter
-
Perf Half Y
-27.14%
-
-
-
-
Beta
0.719
-
-
Volatility
0%, 0.03%
Prev Close
0%
Price
0.51
Change
2%
1110.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.73 | 1.58 | 1.21 | 1.4 | 1.58 | |
| Net income per share | 0.07 | 0.07 | 0.08 | 0.08 | 0.07 | |
| Operating cash flow per share | 0.1 | 0.21 | 0.2 | 0.13 | 0.31 | |
| Free cash flow per share | 0.08 | 0.18 | 0.18 | 0.04 | 0.15 | |
| Cash per share | 0.28 | 0.21 | 0.43 | 0.33 | 0.42 | |
| Book value per share | 0.91 | 0.97 | 0.96 | 1.02 | 1.01 | |
| Tangible book value per share | 0.78 | 0.87 | 0.91 | 1.02 | 0.99 | |
| Share holders equity per share | 0.91 | 0.97 | 0.96 | 1.02 | 1.01 | |
| Interest debt per share | 0.57 | 0.4 | 0.52 | 0.41 | 0.5 | |
| Market cap | 535.32M | 487.65M | 387.77M | 376.2M | 455.42M | |
| Enterprise value | 711.33M | 605.98M | 442.73M | 427.23M | 503.94M | |
| P/E ratio | 13.05 | 11.23 | 7.62 | 7.35 | 10.46 | |
| Price to sales ratio | 0.5 | 0.5 | 0.52 | 0.44 | 0.48 | |
| POCF ratio | 8.58 | 3.67 | 3.14 | 4.63 | 2.44 | |
| PFCF ratio | 10.6 | 4.34 | 3.41 | 16.44 | 4.86 | |
| P/B Ratio | 0.95 | 0.81 | 0.66 | 0.61 | 0.74 | |
| PTB ratio | 0.95 | 0.81 | 0.66 | 0.61 | 0.74 | |
| EV to sales | 0.66 | 0.62 | 0.59 | 0.5 | 0.53 | |
| Enterprise value over EBITDA | 5.98 | 5.1 | 3.53 | 3.7 | 4.34 | |
| EV to operating cash flow | 11.4 | 4.57 | 3.58 | 5.26 | 2.7 | |
| EV to free cash flow | 14.08 | 5.39 | 3.9 | 18.67 | 5.38 | |
| Earnings yield | 0.08 | 0.09 | 0.13 | 0.14 | 0.1 | |
| Free cash flow yield | 0.09 | 0.23 | 0.29 | 0.06 | 0.21 | |
| Debt to equity | 0.6 | 0.38 | 0.52 | 0.39 | 0.47 | |
| Debt to assets | 0.26 | 0.18 | 0.24 | 0.2 | 0.23 | |
| Net debt to EBITDA | 1.48 | 1 | 0.44 | 0.44 | 0.42 | |
| Current ratio | 1.23 | 1.27 | 1.29 | 1.35 | 1.15 | |
| Interest coverage | 4.05 | 4.96 | 4.86 | 6.13 | 5.88 | |
| Income quality | 0.89 | 1.9 | 1.74 | 1.17 | 2.76 | |
| Dividend Yield | 0.04 | 0.03 | 0.03 | 0.01 | 0.03 | |
| Payout ratio | 0.46 | 0.29 | 0.24 | 0.06 | 0.31 | |
| Sales general and administrative to revenue | 0.09 | 0.11 | 0.15 | 0.11 | 0.11 | |
| Research and developement to revenue | 0 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Intangibles to total assets | 0.12 | 0.1 | 0.09 | 0.09 | 0.07 | |
| Capex to operating cash flow | -0.19 | -0.15 | -0.08 | -0.72 | -0.5 | |
| Capex to revenue | -0.01 | -0.02 | -0.01 | -0.07 | -0.1 | |
| Capex to depreciation | -0.41 | -0.56 | -0.29 | -1.68 | -2.43 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.16 | 1.24 | 1.34 | 1.39 | 1.28 | |
| ROIC | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | |
| Return on tangible assets | 0.04 | 0.04 | 0.04 | 0.05 | 0.04 | |
| Graham Net | -0.63 | -0.27 | -0.11 | -0.1 | -0.22 | |
| Working capital | 143.06M | 157.64M | 159.09M | 166.03M | 82.58M | |
| Tangible asset value | 487.87M | 541.66M | 560.55M | 616.24M | 603.39M | |
| Net current asset value | 117.8M | 126.83M | 137.88M | 146.46M | 55.17M | |
| Invested capital | 0.6 | 0.38 | 0.52 | 0.39 | 0.47 | |
| Average receivables | 0 | 139.93M | 263.03M | 242.01M | 210.5M | |
| Average payables | 179.73M | 198.3M | 164.53M | 103.82M | 122.44M | |
| Average inventory | 165.47M | 193.59M | 167.67M | 118.48M | 95.75M | |
| Days sales outstanding | 0 | 104.46 | 120.56 | 102.44 | 69.81 | |
| Days payables outstanding | 80.43 | 116.88 | 79.66 | 66.34 | 74.49 | |
| Days of inventory on hand | 86.6 | 105.37 | 102.17 | 66.74 | 45.49 | |
| Receivables turnover | 0 | 3.49 | 3.03 | 3.56 | 5.23 | |
| Payables turnover | 4.54 | 3.12 | 4.58 | 5.5 | 4.9 | |
| Inventory turnover | 4.21 | 3.46 | 3.57 | 5.47 | 8.02 | |
| ROE | 0.07 | 0.07 | 0.09 | 0.08 | 0.07 | |
| Capex per share | -0.02 | -0.03 | -0.02 | -0.1 | -0.15 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.35 | 0.45 | 0.45 | 0.47 | 0.47 | |
| Net income per share | 0.02 | 0 | 0 | 0.03 | 0.03 | |
| Operating cash flow per share | 0.08 | 0.07 | 0.07 | 0.08 | 0.08 | |
| Free cash flow per share | 0.05 | 0.03 | 0.03 | 0 | 0 | |
| Cash per share | 0.42 | 0.43 | 0.43 | 0.46 | 0.46 | |
| Book value per share | 1.05 | 1.03 | 1.03 | 1.13 | 1.13 | |
| Tangible book value per share | 1.08 | 1.01 | 1.01 | 1.13 | 1.13 | |
| Share holders equity per share | 1.05 | 1.03 | 1.03 | 1.13 | 1.13 | |
| Interest debt per share | 0.41 | 0 | 0.49 | 0 | 0.53 | |
| Market cap | 230.75M | 217.29M | 449.89M | 346.39M | 333.36M | |
| Enterprise value | 239.35M | -24.87M | 498.41M | 89.83M | 379.53M | |
| P/E ratio | 4.76 | -73.81 | -152.82 | 4.59 | 4.42 | |
| Price to sales ratio | 1.1 | 0.81 | 1.67 | 1.25 | 1.21 | |
| POCF ratio | 4.69 | 4.93 | 10.21 | 7.81 | 7.51 | |
| PFCF ratio | 7.64 | 13.32 | 27.58 | 498.41 | 479.65 | |
| P/B Ratio | 0.36 | 0.35 | 0.73 | 0.52 | 0.5 | |
| PTB ratio | 0.36 | 0.35 | 0.73 | 0.52 | 0.5 | |
| EV to sales | 1.14 | -0.09 | 1.85 | 0.32 | 1.37 | |
| Enterprise value over EBITDA | 9.49 | -0.87 | 17.5 | 2.79 | 11.8 | |
| EV to operating cash flow | 4.87 | -0.56 | 11.31 | 2.02 | 8.55 | |
| EV to free cash flow | 7.92 | -1.52 | 30.55 | 129.25 | 546.09 | |
| Earnings yield | 0.05 | 0 | 0 | 0.05 | 0.06 | |
| Free cash flow yield | 0.13 | 0.08 | 0.04 | 0 | 0 | |
| Debt to equity | 0.39 | 0 | 0.47 | 0 | 0.45 | |
| Debt to assets | 0.19 | 0 | 0.23 | 0 | 0.22 | |
| Net debt to EBITDA | 0.34 | -8.5 | 1.7 | -7.98 | 1.44 | |
| Current ratio | 1.32 | 1.15 | 1.15 | 1.1 | 1.1 | |
| Interest coverage | 0 | 0 | 5.23 | 0 | 2.71 | |
| Income quality | 4.06 | -59.89 | -59.89 | 2.35 | 2.35 | |
| Dividend Yield | 0.03 | 0 | 0 | 0.02 | 0.02 | |
| Payout ratio | 0.5 | -0.78 | -0.78 | 0.36 | 0.36 | |
| Sales general and administrative to revenue | 0.11 | 0.11 | 0.11 | 0.09 | 0.09 | |
| Research and developement to revenue | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Intangibles to total assets | 0.08 | 0.07 | 0.07 | 0.07 | 0.07 | |
| Capex to operating cash flow | -0.39 | -0.63 | -0.63 | -0.98 | -0.98 | |
| Capex to revenue | -0.09 | -0.1 | -0.1 | -0.16 | -0.16 | |
| Capex to depreciation | -2.14 | -2.72 | -2.72 | -7.58 | -7.58 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.69 | 0.17 | 0.17 | 0.9 | 0.9 | |
| ROIC | 0.02 | 0.01 | 0.01 | 0.04 | 0.02 | |
| Return on tangible assets | 0.01 | 0 | 0 | 0.01 | 0.01 | |
| Graham Net | -0.11 | -0.22 | -0.22 | -0.27 | -0.27 | |
| Working capital | 163.26M | 82.58M | 82.58M | 57.81M | 57.81M | |
| Tangible asset value | 656.84M | 603.39M | 603.39M | 667.32M | 667.32M | |
| Net current asset value | 144.1M | 55.17M | 55.17M | 29.96M | 29.96M | |
| Invested capital | 0.39 | 0 | 0.47 | 0 | 0.45 | |
| Average receivables | 0 | 187.78M | 183.18M | 181.32M | 179.46M | |
| Average payables | 0 | 127.5M | 138.79M | 142.98M | 147.18M | |
| Average inventory | 0 | 103.74M | 84.76M | 88.03M | 91.29M | |
| Days sales outstanding | 82.52 | 61.28 | 61.28 | 58.41 | 58.41 | |
| Days payables outstanding | 73.16 | 63.39 | 63.39 | 66.51 | 66.51 | |
| Days of inventory on hand | 77.25 | 38.71 | 38.71 | 41.25 | 41.25 | |
| Receivables turnover | 1.09 | 1.47 | 1.47 | 1.54 | 1.54 | |
| Payables turnover | 1.23 | 1.42 | 1.42 | 1.35 | 1.35 | |
| Inventory turnover | 1.17 | 2.32 | 2.32 | 2.18 | 2.18 | |
| ROE | 0.02 | 0 | 0 | 0.03 | 0.03 | |
| Capex per share | -0.03 | -0.05 | -0.05 | -0.07 | -0.07 |
1110.HK Frequently Asked Questions
What is Kingworld Medicines Group Limited stock symbol ?
Kingworld Medicines Group Limited is a CN stock and trading under the symbol 1110.HK
What is Kingworld Medicines Group Limited stock quote today ?
Kingworld Medicines Group Limited stock price is $0.51 today.
Is Kingworld Medicines Group Limited stock public?
Yes, Kingworld Medicines Group Limited is a publicly traded company.
Company Profile
- Volume Average 142.92K
- Market Capitalization 296.23M
- Employee 1K
- CEO Mr. Li Sheng Zhao
- Headquarters Shenzhen,CN
- IPO Date 2010-11-25
-
Website
https://www.kingworld.com.cn 
Kingworld Medicines Group Limited, an investment holding company, distributes branded imported pharmaceutical and healthcare products. The company also supplies pharmaceutical, healthcare, general foodstuffs, and medical products. It offers products for various functional categories, such as cough and phlegm relieving, gastrointestinal, vitamin, orthopedics, cardiovascular, influenza, and other categories under the Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and Mentholatum Product Range brands. The company also manufactures and sells electrotherapeutic and physiotherapeutic devices, and general medical examination devices. It serves in the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and internationally. The company was founded in 1996 and is headquartered in Shenzhen, the People's Republic of China.
